Avalanche Biotechnologies Inc  

(Public, NASDAQ:AAVL)   Watch this stock  
Find more results for Paul Wachter
41.56
+1.64 (4.11%)
Real-time:   11:36AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.00 - 42.98
52 week 22.00 - 62.48
Open 39.32
Vol / Avg. 145,645.00/359,658.00
Mkt cap 1.02B
P/E     -
Div/yield     -
EPS -1.02
Shares 24.84M
Beta     -
Inst. own 61%
Dec 3, 2014
Avalanche Biotechnologies Inc at the 26th Annual Piper Jaffray Healthcare Conference
Nov 20, 2014
Avalanche Biotechnologies Inc at Jefferies Global Healthcare Conference - London
Nov 6, 2014
Avalanche Biotechnologies Inc at Nomura Biotechnology Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -4047.06% -1099.17%
Operating margin -3892.16% -1067.71%
EBITD margin - -547.50%
Return on average assets -29.83% -717.34%
Return on average equity -47.57% -
Employees 26 -
CDP Score - -

Address

1035 O?Brien Drive, Suite A
MENLO PARK, CA 94025
United States - Map
+1-650-2726269 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Avalanche Biotechnologies, Inc. (Avalanche) is clinical-stage biotechnology company. The Company is focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. The Company operates through a single segment, being the business of developing and commercializing therapeutics. Avalanche's Ocular BioFactory platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. The Company�s lead product candidate, AVA-101 is used for the treatment of wet age-related macular degeneration (AMD). The Company�s AVA-201 is a next generation anti-VEGF gene therapy product candidate, which is being developed for the prevention of wet AMD. In addition, Avalanche�s AVA-311 is being developed for the treatment of Juvenile X-linked Retinoschisis (XLRS).

Officers and directors

Mark S. Blumenkranz M.D. Chairman of the Board, Co-Founder
Bio & Compensation  - Reuters
Thomas W. Chalberg Jr., Ph.D. President, Chief Executive Officer, Director
Age: 36
Bio & Compensation  - Reuters
Steven D. Schwartz M.D. Co-Founder, Director
Age: 52
Bio & Compensation  - Reuters
Linda C. Bain CPA Chief Financial Officer, Treasurer
Age: 43
Bio & Compensation  - Reuters
Hans P. Hull J.D. Senior Vice President - Legal and Corporate Development
Age: 39
Bio & Compensation  - Reuters
Roman G Rubio M.D. Senior Vice President and Head - Translational Medicine
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Vice President - Pharmaceutical Development
Age: 47
Bio & Compensation  - Reuters
Samuel B. Barone M.D. Chief Medical Officer
Age: 40
Bio & Compensation  - Reuters
John P. McLaughlin Director
Bio & Compensation  - Reuters
Paul D. Wachter Director
Age: 57
Bio & Compensation  - Reuters